ATE511509T1 - Azaindolylverbindungen und anwendungsverfahren - Google Patents

Azaindolylverbindungen und anwendungsverfahren

Info

Publication number
ATE511509T1
ATE511509T1 AT07854844T AT07854844T ATE511509T1 AT E511509 T1 ATE511509 T1 AT E511509T1 AT 07854844 T AT07854844 T AT 07854844T AT 07854844 T AT07854844 T AT 07854844T AT E511509 T1 ATE511509 T1 AT E511509T1
Authority
AT
Austria
Prior art keywords
methods
application
azaindolyl
compounds
azaindolyl compounds
Prior art date
Application number
AT07854844T
Other languages
English (en)
Inventor
Simon Charles Goodacre
Karen Williams
Stephen Price
Hazel Joan Dyke
John Gary Montana
Mark S Stanley
Liang Bao
Wendy Lee
Original Assignee
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genentech Inc filed Critical Genentech Inc
Application granted granted Critical
Publication of ATE511509T1 publication Critical patent/ATE511509T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AT07854844T 2006-11-30 2007-11-29 Azaindolylverbindungen und anwendungsverfahren ATE511509T1 (de)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US86805506P 2006-11-30 2006-11-30
US91762007P 2007-05-11 2007-05-11
US94474307P 2007-06-18 2007-06-18
PCT/US2007/085962 WO2008067481A1 (en) 2006-11-30 2007-11-29 Aza-indolyl compounds and methods of use

Publications (1)

Publication Number Publication Date
ATE511509T1 true ATE511509T1 (de) 2011-06-15

Family

ID=39169665

Family Applications (1)

Application Number Title Priority Date Filing Date
AT07854844T ATE511509T1 (de) 2006-11-30 2007-11-29 Azaindolylverbindungen und anwendungsverfahren

Country Status (14)

Country Link
US (1) US7855216B2 (de)
EP (1) EP2099796B1 (de)
JP (1) JP5211063B2 (de)
AR (1) AR064031A1 (de)
AT (1) ATE511509T1 (de)
AU (1) AU2007325123B2 (de)
CA (1) CA2672327A1 (de)
CL (1) CL2007003444A1 (de)
DK (1) DK2099796T3 (de)
PE (1) PE20081354A1 (de)
PL (1) PL2099796T3 (de)
PT (1) PT2099796E (de)
TW (1) TW200829586A (de)
WO (1) WO2008067481A1 (de)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010000409A2 (en) * 2008-07-03 2010-01-07 Bayer Schering Pharma Aktiengesellschaft Compounds and processes for production of radiopharmaceuticals
JP5651125B2 (ja) 2008-12-10 2015-01-07 デイナ ファーバー キャンサー インスティチュート，インコーポレイテッド Ｍｅｋ阻害剤に対する耐性を付与するｍｅｋ突然変異
ES2576061T3 (es) 2010-02-25 2016-07-05 Dana-Farber Cancer Institute, Inc. Mutaciones de BRAF que confieren resistencia a inhibidores de BRAF
MX343368B (es) 2010-03-09 2016-11-01 The Broad Inst Inc * Metodo de diagnostico y tratamiento de cancer en pacientes que tienen o desarrollan resistencia a una primera terapia de cancer.
CN103153063B (zh) 2010-07-30 2016-02-17 肿瘤疗法科学股份有限公司 喹啉衍生物及含有其的melk抑制剂
US20150141470A1 (en) 2012-05-08 2015-05-21 The Broad Institute, Inc. Diagnostic and treatment methods in patients having or at risk of developing resistance to cancer therapy
TW201414734A (zh) 2012-07-10 2014-04-16 Takeda Pharmaceutical 氮雜吲哚衍生物
US20150265679A1 (en) 2012-11-02 2015-09-24 The United States Of America, As Represented By Secretary, Department Of Health And Human Services Method of reducing adverse effects in a cancer patient undregoing treatment with a mek inhibitor
UA111925C2 (uk) 2012-12-11 2016-06-24 Федора Фармасьютікалз Інк. БІЦИКЛІЧНІ СПОЛУКИ ТА ЇХ ВИКОРИСТАННЯ ЯК АНТИБАКТЕРІАЛЬНИХ АГЕНТІВ ТА ІНГІБІТОРІВ β-ЛАКТАМАЗИ
US9532987B2 (en) 2013-09-05 2017-01-03 Genentech, Inc. Use of a combination of a MEK inhibitor and an ERK inhibitor for treatment of hyperproliferative diseases
WO2015196072A2 (en) 2014-06-19 2015-12-23 Whitehead Institute For Biomedical Research Uses of kinase inhibitors for inducing and maintaining pluripotency
WO2017180581A1 (en) 2016-04-15 2017-10-19 Genentech, Inc. Diagnostic and therapeutic methods for cancer
US11161845B2 (en) * 2017-05-19 2021-11-02 Nflection Therapeutics, Inc. Pyrrolopyridine-aniline compounds for treatment of dermal disorders
JP7237941B2 (ja) 2017-05-19 2023-03-13 エヌフレクション セラピューティクス インコーポレイテッド 皮膚障害の処置用の融合複素環式芳香族アニリン化合物
KR102811888B1 (ko) 2017-09-08 2025-05-27 에프. 호프만-라 로슈 아게 암의 진단 및 치료 방법
WO2019158579A1 (en) 2018-02-13 2019-08-22 Vib Vzw Targeting minimal residual disease in cancer with rxr antagonists
MA54741A (fr) 2018-11-20 2021-11-24 Nflection Therapeutics Inc Composés thiényl-aniline destinés au traitement d'affections de la peau
CN113473978B (zh) 2018-11-20 2025-03-28 恩福莱克逊治疗有限公司 用于治疗皮肤疾病氰基芳烃-苯胺化合物
CN113473986B (zh) 2018-11-20 2024-10-11 恩福莱克逊治疗有限公司 用于治疗皮肤疾病萘啶酮苯胺化合物
US12371667B2 (en) 2021-05-13 2025-07-29 Washington University Enhanced methods for inducing and maintaining naive human pluripotent stem cells
EP4436570A4 (de) 2021-11-23 2025-10-22 Nflection Therapeutics Inc Formulierungen von pyrrolopyridinanilinverbindungen
EP4469456A1 (de) * 2022-01-28 2024-12-04 Insilico Medicine IP Limited Ektonukleotid-pyrophosphatase-phosphodiesterase 1 (enpp1)-inhibitoren und verwendungen davon
US20250171451A1 (en) * 2022-03-04 2025-05-29 Samjin Pharmaceutical Co., Ltd. Novel heterocyclic compound and pharmaceutical composition comprising same
WO2024033381A1 (en) 2022-08-10 2024-02-15 Vib Vzw Inhibition of tcf4/itf2 in the treatment of cancer
WO2025026383A1 (en) * 2023-08-02 2025-02-06 Insilico Medicine Ip Limited Crytsalline forms of ectonucleotide pyrophosphatase-phosphodiesterase 1 (enpp1) inhibitors and uses thereof
WO2025100940A1 (ko) * 2023-11-07 2025-05-15 보로노이 주식회사 헤테로아릴 유도체 화합물 및 이의 용도

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7235537B2 (en) 2002-03-13 2007-06-26 Array Biopharma, Inc. N3 alkylated benzimidazole derivatives as MEK inhibitors
WO2003091215A1 (en) 2002-04-23 2003-11-06 Aventis Pharmaceuticals Inc. 3-substituted amino-1h-indole-2-carboxylic acid and 3-substituted amino-benzo’ b! thiophene-2-carboxylic acid derivatives as interieukin-4 gene expression inhibitors
US6929411B2 (en) * 2003-09-03 2005-08-16 Hewlett-Packard Development Company, L.P. Selectable control of raster image processor
GB0412914D0 (en) * 2004-06-10 2004-07-14 Oxagen Ltd Compounds
AR049300A1 (es) * 2004-06-15 2006-07-12 Schering Corp Compuestos triciclicos antagonistas de mglur1 como agentes terapeuticos
US7598259B2 (en) * 2004-06-15 2009-10-06 Schering Corporation mGluR1 antagonists as therapeutic agents
DE102005013621A1 (de) * 2005-03-24 2006-09-28 Curacyte Discovery Gmbh Substituierte 2-Aryl(Hetaryl)-5-aminothieno[2,3-d]pyrimidin-6-carbonsäureamide, Verfahren zu ihrer Herstellung und Verwendung als Pharmazeutika
AR070127A1 (es) * 2008-01-11 2010-03-17 Novartis Ag Pirrolo - pirimidinas y pirrolo -piridinas

Also Published As

Publication number Publication date
DK2099796T3 (da) 2011-09-05
PT2099796E (pt) 2011-09-06
JP5211063B2 (ja) 2013-06-12
PE20081354A1 (es) 2008-11-14
EP2099796A1 (de) 2009-09-16
US7855216B2 (en) 2010-12-21
TW200829586A (en) 2008-07-16
CA2672327A1 (en) 2008-06-05
AU2007325123B2 (en) 2012-12-13
AU2007325123A1 (en) 2008-06-05
US20080242655A1 (en) 2008-10-02
HK1135099A1 (en) 2010-05-28
AR064031A1 (es) 2009-03-04
EP2099796B1 (de) 2011-06-01
WO2008067481A1 (en) 2008-06-05
PL2099796T3 (pl) 2011-10-31
CL2007003444A1 (es) 2008-06-27
JP2010511626A (ja) 2010-04-15

Similar Documents

Publication Publication Date Title
ATE511509T1 (de) Azaindolylverbindungen und anwendungsverfahren
ATE531720T1 (de) Aza-benzofuranylverbindungen und anwendungsverfahren dafür
EP2094085A4 (de) Anti-cholesterin-verbindungen und anwendungsverfahren dafür
CY2019010I2 (el) Νεες ενωσεις και συνθεσεις και μεθοδοι χρησης
HUS2100009I1 (hu) Halauxifen-metil és piroxszulam kombinációja
EP2079544A4 (de) Arsenabsorbierende zusammensetzung und verwendungsverfahren
EP2023718A4 (de) Kreatinligandverbindungen und anwendungsverfahren dafür
HRP20151052T1 (xx) Peteroäślani heterocikliäśki amidi i srodne tvari
IL197060A0 (en) Aza-benzothiophenyl compounds and methods of use
DE602007013436D1 (de) N-methylaminomethyl-isoindol-verbindungen und diese enthaltende zusammensetzungen und diese verwendende verfahren
DOP2010000044A (es) Derivado de oxopirazina y herbicida
EP2376085A4 (de) Verbindungen und anwendungsverfahren
DK1940839T3 (da) Pyridopyrimidione Inhibitors of P13Ka
DOP2007000084A (es) Derivados de dihidropirazolopirimidinona
IL198397A0 (en) Anilinopiperazine derivatives and methods of use thereof
DE602006007831D1 (de) N-alkylcarbonylaminosäureester und n-alkylcarbonylaminosäurelaktonverbindungen und anwendung davon
BRPI0906980A2 (pt) Composição de derivados e maleatados
PL2152256T3 (pl) Związki aktywujące telomerazę i sposoby ich zastosowania
IL194028A0 (en) Tetrahydropyridothienopyrimidine compounds and methods of use thereof
CR10562A (es) Nuevos derivados de piridazina
EP2066174A4 (de) Zusammensetzungen mit alpha-1-antitrypsin und verwendungsverfahren dafür
ATE526567T1 (de) Zusammensteller und zusammenstellungsverfahren
HRP20141261T1 (xx) Spojevi tioninija i njihove uporabe
DK2069467T3 (da) Adskillende sammensætninger og fremgangsmåder til anvendelse
BRPI0713736A2 (pt) Derivados de tetralina e indano e emprego destes

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 2099796

Country of ref document: EP